If the effective effects of anti-inflammatory therapy are dominated by limiting the inflammatory response of ischemic or infarcted cardiomyocytes (e.g., IL-6Ra), the use of anti-inflammatory drugs in other atherosclerotic diseases (e.g., stroke, peripheral vascular disease, etc.)may be limited. The gene discussed is IL6R; the disease is vascular disorder.